MX2009004699A - Compuestos de piridinona. - Google Patents
Compuestos de piridinona.Info
- Publication number
- MX2009004699A MX2009004699A MX2009004699A MX2009004699A MX2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A MX 2009004699 A MX2009004699 A MX 2009004699A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridinone compounds
- compound
- directed
- pyridinone
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La invención se dirige a compuestos de piridinona útiles para modular la cinasa Met que tiene la siguiente estructura: (ver fórmula (I)) y se dirige además a composiciones farmacéuticas que comprenden el compuesto; y métodos para tratar enfermedades proliferativas, tales como cáncer por la administración de este compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85754006P | 2006-11-08 | 2006-11-08 | |
PCT/US2007/084047 WO2008058229A1 (en) | 2006-11-08 | 2007-11-08 | Pyridinone compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004699A true MX2009004699A (es) | 2009-05-15 |
Family
ID=39048786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004699A MX2009004699A (es) | 2006-11-08 | 2007-11-08 | Compuestos de piridinona. |
Country Status (21)
Country | Link |
---|---|
US (2) | US7851489B2 (es) |
EP (1) | EP2089364B1 (es) |
JP (1) | JP5276005B2 (es) |
KR (1) | KR101390076B1 (es) |
CN (1) | CN101535264B (es) |
AR (1) | AR063628A1 (es) |
AU (1) | AU2007317296B2 (es) |
CA (1) | CA2669266C (es) |
CL (1) | CL2007003226A1 (es) |
DK (1) | DK2089364T3 (es) |
ES (1) | ES2424851T3 (es) |
HK (1) | HK1131608A1 (es) |
HR (1) | HRP20130626T1 (es) |
MX (1) | MX2009004699A (es) |
NO (1) | NO342395B1 (es) |
PE (1) | PE20081490A1 (es) |
PL (1) | PL2089364T3 (es) |
PT (1) | PT2089364E (es) |
SI (1) | SI2089364T1 (es) |
TW (1) | TWI409259B (es) |
WO (1) | WO2008058229A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101977905B (zh) | 2008-01-23 | 2014-07-02 | 百时美施贵宝公司 | 4-吡啶酮化合物及其对于癌症的用途 |
CA3034994A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders |
EP2563773A1 (en) | 2010-04-29 | 2013-03-06 | Deciphera Pharmaceuticals, LLC | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
MY183769A (en) * | 2010-04-30 | 2021-03-12 | Bristol Myers Squibb Co | Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl-2-oxo-1,2-dihydropyridine-3-carboxamide |
CN102241625B (zh) * | 2010-05-13 | 2014-10-29 | 中南大学 | 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途 |
CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
CN103814016B (zh) * | 2011-06-10 | 2017-03-08 | 默克专利有限公司 | 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法 |
EP2782577A4 (en) | 2011-11-22 | 2015-11-11 | Deciphera Pharmaceuticals Llc | PYRIDONAMIDES AND ANALOGUES WITH ANTIBODY AND ANTIPROLIFERATIVE EFFECT |
EP2879676B1 (en) | 2012-07-28 | 2017-06-14 | Calitor Sciences, LLC | Substituted pyrazolone compounds and methods of use |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
MX2018006207A (es) | 2015-11-19 | 2018-09-05 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
EA201891494A1 (ru) | 2015-12-22 | 2019-01-31 | Инсайт Корпорейшн | Гетероциклические соединения в качестве иммуномодуляторов |
EP3452476B1 (en) | 2016-05-06 | 2021-12-15 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
US20180016260A1 (en) * | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN110072851B (zh) * | 2016-12-19 | 2023-06-06 | 诺华股份有限公司 | 新的吡啶甲酸衍生物及其作为中间体的用途 |
KR20190111025A (ko) | 2016-12-22 | 2019-10-01 | 인사이트 코포레이션 | 면역조절제로서의 벤조옥사졸 유도체 |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
EP3589286B1 (en) | 2017-03-02 | 2022-08-03 | ASLAN Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
CN108623568B (zh) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备 |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2019083455A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS |
WO2019083457A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY |
WO2019083456A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS |
WO2019083458A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA |
EP3719012B1 (en) * | 2017-11-24 | 2024-03-06 | Medshine Discovery Inc. | N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors |
CN111295386B (zh) | 2018-03-08 | 2022-09-06 | 伟迈可生物有限公司 | 噻吩并吡啶衍生物及含有该衍生物的药物组合物 |
SG11202011165TA (en) | 2018-05-11 | 2020-12-30 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
CN112969699A (zh) | 2018-10-09 | 2021-06-15 | 亚狮康私人有限公司 | 瓦利替尼的丙二酸盐 |
WO2020077437A1 (en) * | 2018-10-19 | 2020-04-23 | The University Of British Columbia | Topoisomerase ii catalytic inhibitor compound therapeutics for cancer treatment, methods and uses |
WO2020150307A1 (en) * | 2019-01-15 | 2020-07-23 | The Translational Genomics Research Institute | Phosphonate conjugates and uses thereof |
CN114206883A (zh) | 2019-08-02 | 2022-03-18 | 伟迈可生物有限公司 | 氧代吡啶稠环衍生物及包含该衍生物的药物组合物 |
MX2022001671A (es) | 2019-08-09 | 2022-05-13 | Incyte Corp | Sales de un inhibidor de pd-1/pd-l1. |
CN112771053A (zh) | 2019-09-06 | 2021-05-07 | 伟迈可生物有限公司 | 基于生物标志物的治疗组合物 |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
JP2023513675A (ja) | 2020-02-06 | 2023-04-03 | ウェルマーカー・バイオ・カンパニー・リミテッド | Kras変異に関連する癌の予防または治療のための医薬組成物 |
US20230099204A1 (en) | 2020-03-03 | 2023-03-30 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present |
US20230241073A1 (en) | 2020-05-18 | 2023-08-03 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with ron mutantation, and method using same |
JP2023526444A (ja) | 2020-05-18 | 2023-06-21 | ウェルマーカー バイオ カンパニー リミテッド | Ron変異が関与する膵臓がんの予防又は治療用医薬組成物及びその使用方法 |
JP2023526442A (ja) | 2020-05-18 | 2023-06-21 | ウェルマーカー バイオ カンパニー リミテッド | Ron変異体が関与する小細胞肺がんの予防又は治療用医薬組成物及びその使用方法 |
JP2023548859A (ja) | 2020-11-06 | 2023-11-21 | インサイト・コーポレイション | Pd-1/pd-l1阻害剤ならびにその塩及び結晶形態を作製するためのプロセス |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
CN117355533A (zh) * | 2021-06-22 | 2024-01-05 | 株式会社Lg化学 | 作为蛋白激酶抑制剂的新型化合物 |
US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0430885A3 (en) | 1989-12-01 | 1991-11-06 | Ciba-Geigy Ag | Anthelmintical compounds |
AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
US6429213B1 (en) | 1998-06-17 | 2002-08-06 | Bristol Myers Squibb Pharma Co | Cyclic hydroxamic acids as metalloproteinase inhibitors |
US6521622B1 (en) | 1999-07-20 | 2003-02-18 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
AU7301000A (en) | 1999-09-21 | 2001-04-24 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
SE0102384D0 (sv) | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
AU2002344567A1 (en) | 2001-11-28 | 2003-06-10 | Daiso Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
MXPA06012613A (es) | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2007
- 2007-11-08 KR KR1020097009449A patent/KR101390076B1/ko active IP Right Grant
- 2007-11-08 EP EP07844974.1A patent/EP2089364B1/en active Active
- 2007-11-08 ES ES07844974T patent/ES2424851T3/es active Active
- 2007-11-08 DK DK07844974.1T patent/DK2089364T3/da active
- 2007-11-08 PL PL07844974T patent/PL2089364T3/pl unknown
- 2007-11-08 CL CL200703226A patent/CL2007003226A1/es unknown
- 2007-11-08 TW TW096142253A patent/TWI409259B/zh active
- 2007-11-08 PT PT78449741T patent/PT2089364E/pt unknown
- 2007-11-08 SI SI200731303T patent/SI2089364T1/sl unknown
- 2007-11-08 JP JP2009536476A patent/JP5276005B2/ja active Active
- 2007-11-08 US US11/936,984 patent/US7851489B2/en active Active
- 2007-11-08 MX MX2009004699A patent/MX2009004699A/es active IP Right Grant
- 2007-11-08 AU AU2007317296A patent/AU2007317296B2/en active Active
- 2007-11-08 CN CN2007800414202A patent/CN101535264B/zh active Active
- 2007-11-08 PE PE2007001538A patent/PE20081490A1/es active IP Right Grant
- 2007-11-08 AR ARP070104987A patent/AR063628A1/es active Pending
- 2007-11-08 CA CA2669266A patent/CA2669266C/en active Active
- 2007-11-08 WO PCT/US2007/084047 patent/WO2008058229A1/en active Application Filing
-
2009
- 2009-04-22 NO NO20091605A patent/NO342395B1/no unknown
- 2009-11-02 HK HK09110170.2A patent/HK1131608A1/xx unknown
-
2010
- 2010-11-08 US US12/941,419 patent/US8536200B2/en active Active
-
2013
- 2013-07-03 HR HRP20130626TT patent/HRP20130626T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CL2007003226A1 (es) | 2008-02-08 |
CA2669266C (en) | 2014-04-29 |
HK1131608A1 (en) | 2010-01-29 |
AU2007317296A1 (en) | 2008-05-15 |
PL2089364T3 (pl) | 2013-11-29 |
US8536200B2 (en) | 2013-09-17 |
CN101535264B (zh) | 2012-11-28 |
US20080114033A1 (en) | 2008-05-15 |
TWI409259B (zh) | 2013-09-21 |
CA2669266A1 (en) | 2008-05-15 |
DK2089364T3 (da) | 2013-09-02 |
US20110052583A1 (en) | 2011-03-03 |
NO342395B1 (no) | 2018-05-14 |
TW200829564A (en) | 2008-07-16 |
EP2089364B1 (en) | 2013-06-12 |
CN101535264A (zh) | 2009-09-16 |
JP5276005B2 (ja) | 2013-08-28 |
KR101390076B1 (ko) | 2014-04-29 |
NO20091605L (no) | 2009-05-27 |
WO2008058229A1 (en) | 2008-05-15 |
JP2010509362A (ja) | 2010-03-25 |
AR063628A1 (es) | 2009-02-04 |
US7851489B2 (en) | 2010-12-14 |
KR20090096423A (ko) | 2009-09-10 |
AU2007317296B2 (en) | 2012-07-05 |
PE20081490A1 (es) | 2008-10-30 |
EP2089364A1 (en) | 2009-08-19 |
HRP20130626T1 (en) | 2013-08-31 |
SI2089364T1 (sl) | 2013-10-30 |
ES2424851T3 (es) | 2013-10-09 |
PT2089364E (pt) | 2013-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009004699A (es) | Compuestos de piridinona. | |
UA95644C2 (ru) | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний | |
MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
GEP20135925B (en) | Inhibitors of hedgehog pathway | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
GEP20166484B (en) | Protein kinase inhibitors | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
EP3483143A8 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
WO2008064018A8 (en) | Thienopyrimidinones for treatment of inflammatory disorders and cancers | |
NZ577916A (en) | Cyclopamine analogs | |
UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
MX2009011816A (es) | Derivados de piridina. | |
WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
UA94749C2 (en) | Benzimidazole modulators of vr1 | |
AU2009282962A8 (en) | Compounds as kinase inhibitors | |
WO2008013987A3 (en) | N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |